Welcome to our dedicated page for Treace Medical Concepts news (Ticker: TMCI), a resource for investors and traders seeking the latest updates and insights on Treace Medical Concepts stock.
Treace Medical Concepts, Inc. (TMCI) is a leader in 3D bunion correction and foot/ankle surgical solutions, delivering innovative technologies like the Lapiplasty system. This page provides timely updates on TMCI’s advancements in orthopedic medical devices, financial milestones, and clinical research.
Access press releases covering product launches, regulatory approvals, and partnerships that shape surgical practices. Investors will find earnings reports and strategic updates, while medical professionals can track procedural innovations and training opportunities.
Our curated news collection ensures you stay informed about TMCI’s contributions to reproducible surgical outcomes and cost-effective patient care. Content is verified for accuracy and relevance, offering a neutral perspective on company developments.
Bookmark this page for streamlined access to TMCI’s latest achievements in addressing complex deformities through evidence-based solutions. Regularly updated to reflect the company’s commitment to advancing orthopedic care.
Treace Medical Concepts (Nasdaq: TMCI) announced its participation in the 40th Annual J.P. Morgan Healthcare Conference, scheduled for January 12, 2022, at 4:30 p.m. ET. CEO John T. Treace and CFO Mark L. Hair will present at this prominent event. A live webcast and replay will be accessible on the company's Investor Relations website. Treace specializes in orthopedic medical devices aimed at treating bunions, highlighting their patented Lapiplasty® 3D Bunion Correction™ system and the Adductoplasty™ Midfoot Correction System.
Treace Medical Concepts, Inc. (Nasdaq: TMCI) announced the granting of U.S. Patent No. 11,185,359 for a "Bone Positioning Guide" related to bunion correction surgery. Additionally, the U.S. Patent Office issued a Notice of Allowance for a pending application on similar techniques. These developments enhance Treace's patent portfolio, which now includes over 35 granted patents and 60 pending applications globally. CEO John T. Treace emphasized the importance of these patents in reinforcing the company's commitment to innovation in bunion surgery.
Treace Medical Concepts (Nasdaq: TMCI) has announced participation in the Stifel 2021 Virtual Healthcare Conference on November 15, 2021, at 9:20 am ET. CEO John T. Treace and CFO Mark L. Hair will engage in a fireside chat. The event aims to highlight Treace's advancements in treating hallux valgus (bunions) through their patented Lapiplasty® 3D Bunion Correction™ system and the recently introduced Adductoplasty™ Midfoot Correction System, which addresses complex foot deformities and enhances patient recovery.
Treace Medical Concepts (TMCI) reported Q3 2021 revenue of $21.6 million, marking a 52% increase year-over-year and a 4.7% sequential rise. The gross margin improved to 80.4%, up 80 basis points from the previous year. Key developments included the launch of the Adductoplasty™ System and positive interim data from the ALIGN3D™ clinical study, which showed low recurrence rates post-surgery. Despite pandemic challenges, the firm reaffirms its 2021 revenue guidance of $90 million to $95 million, projecting 57% to 65% growth over 2020.
Treace Medical Concepts (TMCI) announced the granting of U.S. Patent No. 11,147,590 for its bunion surgery method on October 19, 2021, enhancing its patent coverage in bunion correction techniques. This marks the company's 30th U.S. patent, expanding its innovative portfolio initiated in 2014. The new patent complements U.S. Patent No. 10,945,764, granted in March 2021. Treace’s ongoing R&D efforts aim to address patient needs, with over 60 pending patent applications globally, including over 30 in the U.S.
Treace Medical Concepts (TMCI) has announced the release date for its financial results for Q3 2021, scheduled for November 4, 2021, after the trading day ends. A conference call will follow at 4:30 p.m. ET to discuss the financials. Treace, which specializes in orthopaedic devices for bunion treatment, features the patented Lapiplasty® 3D Bunion Correction™ system, aimed at addressing the root causes of bunions and improving patient recovery. An archived webcast of the call will be available on their investor relations website.
Treace Medical Concepts (TMCI) announced the appointments of Betsy Hanna and Deepti Jain to its Board of Directors as of October 1, 2021. With extensive healthcare experience, both aim to guide the company through its growth phase, particularly focusing on the Lapiplasty® system and the new Adductoplasty™ Midfoot Correction System. Chairman James T. Treace expressed confidence in their ability to enhance the board's expertise and drive market penetration.
Treace Medical Concepts (TMCI) has initiated the Mini3D Lapiplasty clinical study, focusing on the Lapiplasty Mini-Incision System for bunion correction. The study aims to evaluate outcomes based on 3D correction with smaller incisions (3.5cm) compared to traditional methods. The primary measure of success will be the recurrence of hallux valgus within 24 months. The study will involve up to 200 patients across 20 centers, building on the previous ALIGN3D study, which has enrolled 173 patients and will conclude in 2023.
Treace Medical Concepts (TMCI) announced positive interim findings from the ALIGN3D™ clinical study on their Lapiplasty® 3D Bunion Correction™ procedure at the 2021 AOFAS Annual Meeting. The study, involving 151 participants, reported an average early weight-bearing return at 8.3 days, significant pain reduction, and a low recurrence rate of only 0.9% at 12 months. Patients also returned to work within 4 weeks and full activity within 4.1 months. Treace continues to strengthen its clinical evidence supporting the Lapiplasty® System, aimed at enhancing bunion surgery outcomes.
Treace Medical Concepts (TMCI) has launched the Adductoplasty™ System, a comprehensive approach for midfoot deformity correction in bunion patients. This system combines implants and precision instruments to ensure consistent realignment and stabilization of the midfoot, which affects up to 30% of hallux valgus cases. CEO John T. Treace highlighted the system's potential to enhance treatment for patients with combined bunion and midfoot issues, addressing a market gap in surgical solutions.
